Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
95
×
biotech
boston blog main
national top stories
boston top stories
clinical trials
national
san francisco blog main
san francisco top stories
new york blog main
fda
new york top stories
san diego blog main
boston
san diego top stories
raleigh-durham blog main
raleigh-durham top stories
deals
cancer
detroit blog main
detroit top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
seattle blog main
seattle top stories
startups
texas top stories
europe blog main
texas blog main
boulder/denver blog main
boulder/denver top stories
europe top stories
investing
novartis
amgen
roche
eli lilly
What
medicines
drug
new
fda
medicine
bio
ipo
life
medical
roundup
cancer
therapeutics
biotech
sciences
drugs
research
health
team
tech
xcelerating
approval
breakthroughs
company
digital
learn
plans
accelerating
attend
biopharma's
biopharma’s
boston
companies
deal
developing
disease
future
join
raised
registering
therapy
Language
unset
95
×
Current search:
unset
×
" national blog main "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Explore San Diego’s Precision Medicine and Genomics Sector in Xconomy’s New Podcast and Special Report
@xconomy.com
4 years ago
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity
@xconomy.com
4 years ago
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
@xconomy.com
4 years ago
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
First
Prev
Page 1
(current)
Next
Last